Form 4: Interparfums Director Reports New Stock Option Grants
Insider Transaction Report
Interparfums Director Veronique Gabai-Pinsky reported beneficial ownership of various stock options, including new grants on December 31, 2025, under a Rule 10b5-1 plan.
Summary
- Veronique Gabai-Pinsky, a Director of Interparfums Inc. (IPAR), filed a Form 4 to report changes in beneficial ownership of company securities.
- The filing indicates the acquisition of 1,500 stock options on December 31, 2025, with an exercise price of $84.64 per share. These options become exercisable in annual installments of 300 options each, from December 31, 2026, through December 31, 2030, and expire on December 30, 2031.
- This transaction was executed pursuant to a Rule 10b5-1(c) plan, which allows insiders to pre-plan stock transactions to avoid accusations of trading on material non-public information.
- Following this transaction, Ms. Gabai-Pinsky beneficially owns a total of 6,000 stock options. These include 1,500 options with an exercise price of $97.84, 1,500 options with an exercise price of $147.71, 1,500 options with an exercise price of $130.60, and the newly acquired 1,500 options with an exercise price of $84.64.
- The options have various transaction (grant) dates ranging from December 31, 2023, to December 31, 2025, and expiration dates up to December 30, 2031.
Sentiment
Score: 5
Explanation: This is a routine insider transaction filing (Form 4) reporting stock option grants to a director. It does not contain financial performance data or strategic announcements that would typically influence sentiment positively or negatively. The use of a Rule 10b5-1 plan is a standard practice for pre-planned transactions.
Positives
- The acquisition of stock options by a director aligns their interests with those of shareholders, incentivizing long-term company performance.
- The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating pre-planned transactions designed to avoid concerns about insider trading.
Future Outlook
The filing does not provide any specific forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on the director's beneficial ownership of derivative securities.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, specifically the grant of stock options to a director. Such equity compensation is a common practice across industries to incentivize management and align their interests with shareholders. The use of a Rule 10b5-1 plan is a standard corporate governance practice for pre-planned insider transactions.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Policy Adherence | The reported transaction was made pursuant to a Rule 10b5-1(c) plan, which is a corporate governance best practice for insiders to pre-plan stock transactions to avoid accusations of trading on material non-public information. | 12/31/2025 | Enhances transparency and reduces potential for insider trading allegations, reinforcing good corporate governance practices. |
Related Party Transactions
- The stock option grants to Veronique Gabai-Pinsky, a director, represent a form of equity compensation from Interparfums Inc. to a related party. This is a standard practice for executive and director remuneration.
Stakeholder Impact
- Shareholders: The grant of stock options to a director further aligns their financial interests with those of the shareholders, potentially motivating decisions that enhance long-term shareholder value.
- Employees: No direct impact on general employees is indicated by this filing.
- Customers: No direct impact on customers is indicated by this filing.
- Suppliers: No direct impact on suppliers is indicated by this filing.
- Creditors: No direct impact on creditors is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 12/31/2023 | Transaction Date for 300 options with an exercise price of $97.84, expiring 12/30/2028. |
| 12/31/2024 | Transaction Date for 300 options with an exercise price of $97.84, expiring 12/30/2028. |
| 12/29/2024 | Transaction Date for 300 options with an exercise price of $147.71, expiring 12/28/2029. |
| 12/31/2025 | Date of Earliest Transaction for this filing; Transaction Date for 300 options with an exercise price of $97.84, expiring 12/30/2028; Transaction Date for 300 options with an exercise price of $130.60, expiring 12/30/2030; Acquisition date for 1,500 options with an exercise price of $84.64, expiring 12/30/2031. |
| 12/29/2025 | Transaction Date for 300 options with an exercise price of $147.71, expiring 12/28/2029. |
| 01/05/2026 | Date the Form 4 was signed by Veronique Gabai-Pinsky's attorney-in-fact. |
| 12/31/2026 | Transaction Date for 300 options with an exercise price of $97.84, expiring 12/30/2028; Transaction Date for 300 options with an exercise price of $130.60, expiring 12/30/2030; Earliest exercisable date for 300 options from the 12/31/2025 grant ($84.64 exercise price). |
| 12/29/2026 | Transaction Date for 300 options with an exercise price of $147.71, expiring 12/28/2029. |
| 12/31/2027 | Transaction Date for 300 options with an exercise price of $97.84, expiring 12/30/2028; Transaction Date for 300 options with an exercise price of $130.60, expiring 12/30/2030; Exercisable date for 300 options from the 12/31/2025 grant ($84.64 exercise price). |
| 12/29/2027 | Transaction Date for 300 options with an exercise price of $147.71, expiring 12/28/2029. |
| 12/30/2028 | Expiration Date for 1,500 options with an exercise price of $97.84. |
| 12/31/2028 | Transaction Date for 300 options with an exercise price of $130.60, expiring 12/30/2030; Exercisable date for 300 options from the 12/31/2025 grant ($84.64 exercise price). |
| 12/28/2029 | Expiration Date for 1,500 options with an exercise price of $147.71. |
| 12/31/2029 | Transaction Date for 300 options with an exercise price of $130.60, expiring 12/30/2030; Exercisable date for 300 options from the 12/31/2025 grant ($84.64 exercise price). |
| 12/30/2030 | Expiration Date for 1,500 options with an exercise price of $130.60; Exercisable date for 300 options from the 12/31/2025 grant ($84.64 exercise price). |
| 12/30/2031 | Expiration Date for 1,500 options with an exercise price of $84.64. |
Keywords
Interparfums, IPAR, Form 4, SEC filing, insider transaction, stock options, beneficial ownership, corporate governance, director compensation, equity compensation, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.